Kawin released its performance for the first three quarters, with a net profit attributable to the parent company of 103 million yuan, a year-on-year decrease of 5.14%

According to the Zhitong Finance APP, Kawin disclosed its third-quarter report for 2025. The company achieved revenue of 927 million yuan in the first three quarters, a year-on-year decrease of 8.29%; the net profit attributable to shareholders of the listed company was 103 million yuan, a year-on-year decrease of 5.14%; the net profit excluding non-recurring gains and losses was 100 million yuan, a year-on-year decrease of 9.05%; the basic earnings per share were 0.612 yuan

Kawin released its semi-annual performance, with a net profit attributable to the parent company of 47.38 million yuan, a year-on-year increase of 11.75%

Kawin released its semi-annual performance for 2025, with revenue of 566 million yuan, a year-on-year decrease of 5.05%; net profit attributable to the parent company of 47.38 million yuan, a year-on-year increase of 11.75%; net profit excluding non-recurring items of 46.41 million yuan, a year-on-year increase of 3.93%; basic earnings per share of 0.28 yuan. The growth in net profit attributable to the parent company is mainly due to the implementation of the centralized procurement policy for Jinshuxi® and Kaiyin Probiotics®, as well as the company's cost reduction and efficiency enhancement measures, which improved profitability

Kawin's multiple shareholders completed a reduction in holdings, totaling a 3% decrease in shares

According to the Zhitong Finance APP, Kawin announced that the company has received notification letters from Fushan Bay, Funing Bay, Zhuoshang Stone, and Zhuoshang Bay, stating that the aforementioned shareholders' reduction plan has been completed. During the reduction plan period, Fushan Bay, Funing Bay, Zhuoshang Stone, and Zhuoshang Bay cumulatively reduced their holdings of the company's shares by 5.128 million shares through block trades and centralized bidding transactions, accounting for 3.00% of the company's total share capital

Kawin: Shareholders collectively reduced their holdings by 2.86% of the company's shares

Kawin announced that shareholders reduced their holdings in the company by 4.8908 million shares through block trading and centralized bidding, accounting for 2.86% of the total share capital. The shareholding ratio of the information disclosure obligor and its concerted parties decreased from 27.86% to 25.00%. Before the change, they held a total of 51.3869 million shares, accounting for 30.26% of the total share capital; after the change, the number of shares held decreased to 42.7361 million shares, accounting for 25.00% of the total share capital

The A-share biopharmaceutical sector saw a short-term surge, with Sunshine Guojian Pharmaceutical rising over 10%. InnoCare Pharma, RemeGen, Maiwei Biotech, Kawin, and Zhixiang Jintai also followed suit